Role of natural killer cells in hematopoietic stem cell transplantation: Myth or reality?

Journal of Innate Immunity

Volumn 3, Issue 4, 2011, Pages 383-394

  Nguyen, Stéphanie ^a,b   Béziat, Vivien ^a,b   Roos Weil, Damien ^a   Vieillard, Vincent ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Clinical outcome; Graft versus leukemia effect; Hematopoietic transplantation; Natural killer cells

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2A;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; BIOLOGICAL MODEL; CANCER RELAPSE; CELL FUNCTION; GENOTYPE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOINCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW;

CLINICAL TRIALS AS TOPIC; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; RECEPTORS, NATURAL KILLER CELL; TREATMENT OUTCOME;

EID: 79959634359     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000323935     Document Type: Review

References (57)

1. Moretta A, Locatelli F, Moretta L: Human NK cells: from HLA class I-specific killer Iglike receptors to the therapy of acute leuke-mias. Immunol Rev 2008; 224: 58-69.
2. Long EO: Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008; 224:70-84.
3. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P: Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997; 7: 739 - 751.
4. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D, Parham P: Genetic control of human NK cell repertoire. J Immunol 2002; 169: 239-247.
5. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P: MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008; 112:2369-2380.
6. Brodin P, Kärre K, Höglund P: NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009; 30:143-149.
7. Parham P: MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214.
8. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100.
9. Ruggeri, L Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-440.
10. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socié G, Rio B, Sirvent A, Renaud M, Madero L, Mohty M, Ferra C, Garnier F, Loiseau P, Garcia J, Lecchi L, Kögler G, Beguin Y, Navarrete C, Devos T, Ionescu I, Boudjedir K, Herr AL, Gluckman E, Rocha V, Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT: KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23: 492-500.
11. Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, Grosse-Wilde H: Genotypic inhibitory killer immu-noglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105:2594-2600.
12. Elmaagacli AH, Ottinger H, Koldehoff M, Peceny R, Steckel NK, Trenschel R, Biersack H, Grosse-Wilde H, Beelen DW: Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor. Trans-plantation 2005; 79: 1741-1747.
13. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102: 814-819.
14. Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, Nagler A, Slavin S: The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004; 63:204-211.
15. De Santis D, Bishara A, Witt CS, Nagler A, Brautbar C, Slavin S, Christia nsen FT: Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 2005; 65: 519-528.
16. Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, DeFor T, Verneris MR, Blazar BR, Miller JS: Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009; 113:5628-5634.
17. Bornhäuser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G: Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004; 103:2860-2861.
18. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100: 3825-3857.
19. Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP: Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007; 21:848-851.
20. Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuk F, Dahlke J, Eiermann T, Zander A: Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006; 82: 1024-1030.
21. Morishima Y, Yabe T, Matsuo K, Kashiwase K, Inoko H, Saji H, Yamamoto K, Maruya E, Akatsuka Y, Onizuka M, Sakamaki H, Sao H, Ogawa S, Kato S, Juji T, Sasazuki T, Kodera Y, Japan Marrow Donor Program: Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing tr a nsplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007; 13: 315-328.
22. Schaffer, M, Malmberg KJ, Ringdén O, Ljunggren HG, Remberger M: Increased infection-related mortality in KIR-ligand-mis-matched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78:1081-1085.
23. Sun JY, Gaidulis L, Dagis A, Palmer J, Rodriguez R, Miller MM, Forman SJ, Senitzer D: Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 2005; 36: 525-530.
24. Yabe T, Matsuo K, Hirayasu K, Kashiwase K, Kawamura-Ishii S, Tanaka H, Ogawa A, Takanashi M, Satake M, Nakajima K, Tokunaga K, Inoko H, Saji H, Ogawa S, Juji T, Sasazuki T, Kodera Y, Morishima Y, Japan Marrow Donor Program: Donor killer immuno-globulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14: 75-87.
25. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM, KIR Study Group, Center for International Blood and Marrow Transplantation Research: The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12:876-884.
26. Lowe EJ, Turner V, Handgretinger R, Horwitz EM, Benaim E, Hale GA, Woodard P, Leung W: T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003; 123:323-326.
27. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF: Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
28. Leung W, Lyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R: Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650.
29. Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B, Gastl G, Nachbaur D: Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Med 2007; 148:520-528.
30. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.
31. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ: Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109:5058-5061.
32. Sobecks RM, Ball EJ, Maciejewski JP, Rybicki LA, Brown S, Kalaycio M, Pohlman B, Andresen S, Theil KS, Dean R, Bolwell BJ: Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 2007; 39:417-424.
33. La Nasa G, Littera R, Locatelli F, Giardini C, Ventrella A, Mulargia M, Vacca A, Orrù N, Orrù S, Piras E, Giustolisi G, Lisini D, Nesci S, Caocci G, Carcassi C: Status of donor-recipient HLA class I ligands and not the KIR genotype is predictive for the outcome of unrelated hematopoietic stem cell transplantation in beta-thalassemia patients. Biol Blood Marrow Tra nsplant 2007; 13: 1358-1368.
34. Hsu KC, Pinto-Agnello C, Gooley T, Malkki M, Dupont B, Petersdorf EW: Hematopoiet ic stem cell transplantation: killer immuno-globulin-like receptor component. Tissue Antigens 2007; 69:42-45.
35. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC: Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood, 2009; 113:3875-3884.
36. Björklund AT, Schaffer M, Fauriat C, Ringdén O, Remberger M, Hammarstedt C, Barrett AJ, Ljungman P, Ljunggren HG, Malmberg KJ: NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010; 115: 2686-2694.
37. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, Darbyshire P, Lawson S, Boxall E, Moss P: Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006; 107: 1230-1232.
38. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ: Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113: 726-732.
39. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-2419.
40. Kim HJ, Choi Y, Min WS, Kim TG, Cho BS, Kim SY, Eom KS, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim CC: The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation 2007; 84:1082-1091.
41. Ludajic K, Balavarca Y, Bickeböller H, Rosenmayr A, Fae I, Fischer GF, Kouba M, Pohlreich D, Kalhs P, Greinix HT: KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation. Bone Marrow Transplant 2009; 44: 97-103.
42. Verheyden S, Schots R, Duquet W, Demanet C: A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-1451.
43. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, Moss PA, Briggs DC: The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103:1521-1526.
44. Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F, Chéneau ML, Schleinitz N, Cesbron A, Folléa G, Harrousseau JL, Bignon JD: Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63:271-280.
45. Giebel S, Nowak I, Dziaczkowska J, Czerw T, Wojnar J, Krawczyk-Kulis M, Holowiecki J, Holowiecka-Goral A, Markiewicz M, Kopera M, Karolczyk A, Kyrcz-Krzemien S, Kusnierczyk P: Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc 2006; 38:287-291
46. McQueen KL, Dorighi KM, Guethlein LA, Wong R, Sanjanwala B, Parham P: Donorrecipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007; 68:309-323.
47. Schellekens J, Rozemuller EH, Petersen EJ, van den Tweel JG, Verdonck LF, Tilanus MG: Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. Mol Immunol 2008; 45: 2255-2261.
48. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Al Jijakli A, Rouas-Freiss N, Carosella ED, Boudifa A, Debré P, Vieillard V: NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005; 105:4135-4142.
49. Freud AG, Caligiuri MA: Human natural killer cell development. Immunol Rev 2006; 214: 56-72.
50. Vago L, Forno B, Sormani MP, Crocchiolo R, Zino E, Di Terlizzi S, Lupo Stanghellini MT, Mazzi B, Perna SK, Bondanza A, Middleton D, Palini A, Bernardi M, Bacchetta R, Peccatori J, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K: Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008; 112:3488-3499.
51. Nguyen S, Kuentz M, Vernant JP, Dhedin N, Bories D, Debré P, Vieillard V: Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008; 22: 344-352.
52. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, Miller JS: KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106:4370-4376.
53. Eissens DN, Schaap NP, Preijers FW, Dolstra H, van Cranenbroek B, Schattenberg AV, Joosten I, van der Meer A: CD3+/CD19+-de-pleted graf ts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia 2010; 24: 583-591.
54. Pfeiffer MM, Feuchtinger T, Teltschik HM, Schumm M, Müller I, Handgretinger R, Lang P: Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in chi ldren. Haematologica 2010; 95: 1381-1388.
55. Fischer JC, Ottinger H, Ferencik S, Sribar M, Punzel M, Beelen DW, Schwan MA, Grosse-Wilde H, Wernet P, Uhrberg M: Relevance of C1 and C2 epitopes for hematopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol 2007; 178: 3918-3923.
56. Beziat V, Nguyen S, Lapusan S, Hervier B, Dhedin N, Bories D, Uzunov M, Boudifa A, Trebeden-Negre H, Norol F, Marjanovic Z, Marie JP, Vernant JP, Debre P, Rio B, Vieillard V: Fully functional NK cells after unrelated cord blood transplantation. Leukemia 2009; 23: 721-728.
57. Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR, Cooley S, Wangen R, Fautsch SK, Nicklow R, Defor T, Blazar BR: Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110:2761-2763.